Global Guidance

Global guidance helps set expectations, define priorities and can pave the way for national action.


For quick facts on WHO's updated PrEP recommendation, click here.

For the full report, click below.
Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection — Second edition
In June 2016, WHO released guidelines on the diagnosis of HIV infection, the use of ARVs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention, treatment and care. This edition updates the 2013 consolidated guidelines on the use of antiretroviral drugs following an extensive review of evidence and consultations in mid-2015.

Oral Pre-Exposure Prophylaxis–Putting a New Choice in Context
This 2015 publication, produced collaboratively between UNAIDS, WHO and AVAC, is intended to complement forthcoming WHO recommendations and support the optimal use of oral PrEP to protect individuals and contribute to ending the AIDS epidemic.

Recommendations on the Use of Daily oral PrEP for All Populations – PEPFAR Scientific Advisory Board (SAB)
Created in late 2015 by PEPFAR’s PrEP Expert Working Group for the PEPFAR Scientific Advisory Board, this report explores the logistics, support and priorities needed for PEPFAR-funded programs to successfully implement PrEP.

Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations
In 2014, WHO updated its Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection to include a recommendation of PrEP as a prevention option for gay men and other men who have sex with men; this document also recognizes the utility of PrEP for serodiscordant couples in some contexts.

PrEP Demonstration Projects: A Framework for Country Level Protocol Development
Issued by the World Health Organization in 2013.

Guidance on Pre-Exposure Oral Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women Who Have Sex with Men at High Risk of HIV
Issued by the World Health Organization in 2012.

This page will be updated as additional global guidance and decision-maker tools are developed and disseminated by WHO and UNAIDS.

News Spotlight

  • FDA Approves Truvada as PrEP for Adolescents at Risk for HIV

    May 15, 2018

    The US Food and Drug Administration has expanded the approval of Truvada as pre-exposure prophylaxis (PrEP) against HIV to include adolescents. Truvada was approved as an HIV prevention method in 2012 but only for individuals age 18 and older. The new approval expands this indication to include adults and adolescents at risk for HIV.

    Read more

  • Early PrEP Uptake in Africa Study Gives Support for Possibility of Wider Acceptance

    May 9, 2018

    New findings show that nearly a fifth of adults whose risk for HIV infection made them eligible for free PrEP started taking the drug within 30 days — according to a study examining the impacts of health interventions across communities in two East African countries. The study’s authors conclude that this provides further evidence that widespread roll out of PrEP to individuals at high risks for infection across resource-limited communities is feasible.

    Read more